Related Experiment Videos

[Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary

1

  • 1Copenhagen Trial Unit (CTU), Center for Klinisk Interventionsforskning, Rigshospitalet, DK-2100 København Ø. cgluud@ctu.rh.dk.

Ugeskrift for Laeger
|February 17, 2007
PubMed

Insights

The CLARICOR trial found that clarithromycin antibiotic treatment significantly increased cardiovascular mortality in patients with coronary heart disease. Further safety studies are needed for this antibiotic in cardiac patients.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Context:

  • Stable coronary heart disease (CHD) patients are at risk for cardiovascular events.
  • Antibiotics are sometimes investigated for potential cardiovascular benefits.
  • The CLARICOR trial assessed clarithromycin's effect on cardiovascular outcomes.

Purpose:

  • To evaluate the safety and efficacy of clarithromycin in patients with stable coronary heart disease.
  • To determine if antibiotic treatment with clarithromycin reduces cardiovascular morbidity or mortality.

Summary:

  • The CLARICOR trial randomized 4372 stable coronary heart disease patients to receive either clarithromycin (500 mg daily for two weeks) or a placebo.
  • After a median follow-up of 2.6 years, significantly increased cardiovascular mortality was observed in the clarithromycin group compared to placebo.
  • No evidence supported a preventive effect of antibiotics on coronary heart disease.

Impact:

  • Results indicate a potential increased risk of cardiovascular mortality with clarithromycin use in CHD patients.
  • Highlights the need for rigorous safety evaluations of antibiotics in cardiovascular populations.
  • Challenges the hypothesis of using antibiotics for cardiovascular disease prevention.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...